myPeptides
English

All content is for general information only — not medical advice, not a dosing or usage recommendation, and not a claim of efficacy. Many substances are not approved as medicines or are prescription-only; whether possession and use are legal depends on the law of your country of residence and is your own responsibility. myPeptides does not sell or supply any substances — it is an information and organization tool. For health questions, consult a licensed physician or pharmacist.

Mazdutide vs Tirzepatide: differences, evidence and safety

Updated September 25, 202612 min

Mazdutide vs Tirzepatide: differences, evidence and safety

Answer first

Mazdutide switches on the receptors for two hormones, GLP-1 and glucagon, and only China has licensed it. Tirzepatide switches on the receptors for GIP and GLP-1. It is an approved prescription medicine in eight markets, including the United States and the European Union. No study comparing the two directly could be found, so their trial figures cannot be ranked.

At a glance

AttributeMazdutideTirzepatide
Substance classIncretins & metabolicIncretins & metabolic
Legal categoryPrescription medicinePrescription medicine
Approval status by market
United StatesInvestigationalApproved, prescription only (2022-05-13)
European UnionInvestigationalApproved, prescription only (2022-09-15)
GermanyInvestigationalApproved, prescription only (2022-09-15)
United KingdomInvestigationalApproved, prescription only (2023-11-08)
AustraliaNot approvedApproved, prescription only (2023-07-10)
CanadaNot approvedApproved, prescription only (2022-11-24)
SwitzerlandNot approvedApproved, prescription only (2022-11-02)
WADA statusNot listed (2026)Not listed (2026)
Development stageApprovedApproved
Strongest evidencePhase 3 randomised trialPhase 3 randomised trial
Registered trials (ClinicalTrials.gov)1215+
Sequence length34 amino acidsNot established
Molecular weight4476 g/mol4813.53 g/mol
Last verified2026-09-102026-09-06

How they work

Both are peptides made in the laboratory, and both molecules were designed by the same company, Eli Lilly [1], [2]. Each carries a fatty acid chain of twenty carbons on the building block at position 20, a lysine. That chain makes the peptide cling to albumin, a carrier protein in the blood, so the body clears it slowly [1], [3], [2].

Mazdutide

  • Two receptors, GLP-1 and glucagon. It is a chain of 34 amino acids that copies oxyntomodulin, a hormone the gut releases after a meal [1].
  • The GLP-1 part. Switching this receptor on prompts insulin release when blood sugar is high, slows the stomach down and dampens appetite [4].
  • The glucagon part. The idea is that it raises the energy the body burns and makes the liver burn more fat. A direct measurement of this in people could not be found in the published trials [5].
  • Both routes seem to count. In laboratory animals weight still fell when either receptor was disabled. How much each one adds in humans remains an assumption [5], [4].

Tirzepatide

  • Two receptors, GIP and GLP-1. It is a chain of 39 amino acids built on the template of GIP (glucose-dependent insulinotropic polypeptide), another gut hormone [2].
  • Stomach and appetite. Switching on the GLP-1 receptor slows the emptying of the stomach and makes people eat less [2].
  • Insulin and glucagon. According to the label, the body releases more insulin and less glucagon, the hormone that pushes blood sugar up. Both effects only come into play when blood sugar is high [2].

The GLP-1 receptor is shared. The second target is the core difference: tirzepatide adds GIP, mazdutide adds glucagon itself. A trial that separates what each receptor contributes in people could not be found for either drug [5], [2].

The body takes about five days to clear half a dose of tirzepatide [2]. For mazdutide the figure varies widely. In an early study of 24 participants it ranged from 174.8 to 1,075.7 hours, that is 7.3 to 44.8 days [3].

What the studies show

No study that compares mazdutide and tirzepatide directly could be found in the published record reviewed for this page. Mazdutide's head-to-head trial DREAMS-3 uses semaglutide as the comparator, not tirzepatide, and by 10 September 2026 no results from it could be found [6].

Everything below therefore comes from separate trials. They enrolled different people, gave different doses, measured different endpoints and ran for different lengths of time. Their numbers cannot be set against each other. Almost every mazdutide participant so far has been Chinese; the American mid-stage trial enrolled 179 people [7].

Weight in adults with obesity

Phase 3 RCT GLORY-1 randomised 610 Chinese adults to one of two mazdutide dose levels or a dummy injection. By week 48 the two treated groups had lost 11.00% and 14.01% of body weight, while the placebo group gained 0.30% [8].

Phase 3 RCT GLORY-2 enrolled 461 Chinese adults with obesity. After 60 weeks the mazdutide group had lost 16.65% of body weight, against 1.50% on placebo [9].

Phase 2 RCT A mid-stage mazdutide trial in the United States enrolled 179 American adults. At week 32 the three treated groups had lost 7.3%, 15.6% and 18.1%, against 0.9% on placebo. In the highest dose group, 20% stopped because of side effects [7].

Phase 3 RCT SURMOUNT-1 allocated 2,539 adults with obesity and without diabetes at random to tirzepatide or a dummy injection for 72 weeks. Average weight fell by 15.0%, 19.5% and 20.9% across the three doses tested, against 3.1% on placebo [10].

Meta-analysis A 2026 review pooled nine randomised mazdutide trials with 2,292 participants. It rated the weight evidence in people without diabetes as very low in certainty, because the trials were few and differed widely. In type 2 diabetes the evidence was graded moderate [11].

Weight and blood sugar in type 2 diabetes

Both drugs were tested on glycated haemoglobin, a blood value that reflects average blood sugar over the past two to three months.

Phase 3 RCT DREAMS-1 enrolled 320 Chinese adults whose diabetes was not controlled by diet and exercise. From a starting value of 8.24%, the reading fell by 1.57 and 2.15 percentage points over 24 weeks, against 0.14 on placebo. Weight fell by 5.61% and 7.81%, against 1.26% [12].

Phase 3 RCT SURPASS-1 enrolled 478 adults with type 2 diabetes who had not yet taken any diabetes medicine. After 40 weeks the value fell by 1.87 to 2.07 points from a starting level of 7.9%. On placebo it crept up by 0.04 points [13].

Phase 3 RCT SURMOUNT-2 enrolled 938 adults with obesity and type 2 diabetes. By week 72 the two tirzepatide groups had lost 12.8% and 14.7% of their weight [14].

Against the same older drug, dulaglutide

Each drug has been tested against dulaglutide, an established weekly injection, but in trials that asked different questions.

Phase 3 RCT, active comparator DREAMS-2 enrolled 731 Chinese adults with type 2 diabetes already taking tablets for it. Over 28 weeks both mazdutide doses lowered blood sugar more than dulaglutide, by 0.24 points (p = 0.0032) and 0.30 points (p = 0.0003). Stomach and bowel problems were more common on mazdutide [15].

Phase 3 RCT, active comparator SURPASS-CVOT followed 13,299 adults with type 2 diabetes and hardened arteries for a median of 210.1 weeks. A serious heart event occurred in 12.2% on tirzepatide and 13.1% on dulaglutide [16].

That is a risk 8% lower (hazard ratio 0.92), but the range compatible with the data, 0.83 to 1.01, included no difference at all. Tirzepatide proved no worse than dulaglutide (p = 0.003); being better was tested and not shown (p = 0.09) [16].

One trial measured blood sugar over 28 weeks, the other heart events over roughly four years. The shared comparator does not turn them into a comparison of mazdutide with tirzepatide.

Against semaglutide

Phase 3 RCT, open-label SURPASS-2 enrolled 1,879 adults with type 2 diabetes already taking metformin. The blood sugar value fell by 2.01, 2.24 and 2.30 points across the three tirzepatide doses, compared with 1.86 points on semaglutide [17].

Phase 3 RCT, open-label SURMOUNT-5 compared tirzepatide with semaglutide in 751 adults with obesity and without diabetes. At week 72 average weight loss was 20.2% against 13.7%. Everyone knew which drug was being given, which can colour how results are judged [18].

No results yet DREAMS-3 compares mazdutide with semaglutide in 349 Chinese adults with type 2 diabetes and obesity. Its main measurement date passed on 17 September 2025, but by 10 September 2026 only the design and baseline paper could be found [6].

Heart

Phase 3 RCT SUMMIT followed 731 people with obesity and the stiff form of heart failure for a median of 104 weeks. Heart death or worsening heart failure occurred in 9.9% on tirzepatide and 15.3% on placebo (hazard ratio 0.62, range 0.41 to 0.95) [19].

For mazdutide, no heart or kidney outcome trial could be found, either published or, on the evidence of the registry, started [11], [20].

Liver

Phase 2 RCT SYNERGY-NASH treated 190 adults for 52 weeks whose fatty liver had become inflamed and scarred (fibrosis F2 or F3). Of these, 157 had an assessable follow-up tissue sample. Among them, the inflammation cleared without worse scarring in 44%, 56% and 62% on tirzepatide, against 10% on placebo [21].

Animal data Forty-two male mice were fed a high-fat diet for 13 weeks, then treated for four weeks. Liver fat on a scan fell further on mazdutide than on a single-hormone comparator, by a middle value of 5.59% against 3.30% [22]. No human liver-fat results for mazdutide could be found; trials in fatty liver are running in China [20].

Keeping the weight off

Phase 3 RCT, randomised withdrawal SURMOUNT-4 first gave all 670 adults with obesity tirzepatide openly for 36 weeks. Between week 36 and week 88 those who carried on lost a further 5.5%, while those switched to placebo regained 14.0% [23].

No published mazdutide trial longer than 60 weeks could be found, nor any report of what happens to weight after the injections stop [9].

Outcomes studied for only one of the two

  • Tirzepatide and sleep apnoea. SURMOUNT-OSA enrolled 469 adults with obesity and moderate to severe obstructive sleep apnoea. By week 52 breathing interruptions fell by 20.0 and 23.8 events per hour of sleep more than on placebo [24].
  • Mazdutide in special groups. Trials in sleep apnoea and in adolescents are running in China. Trials in impaired kidney and liver function are complete or running; no results from them could be found by 10 September 2026 [20].

Safety

The two safety records come from different kinds of source. Tirzepatide's figures come from approved US product information that pools its weight-loss trials. Mazdutide's come from published trials run almost entirely in China. The lists below are therefore not a ranking.

Mazdutide. The main figures come from GLORY-2, the longest trial, comparing the treated group with placebo [9].

  • Stomach and bowel. Vomiting affected 53.1% against 1.3%, nausea 46.9% against 3.2% and diarrhoea 39.4% against 6.5%. Most cases were described as mild or moderate [9].
  • Stopping treatment. Side effects ended participation for 2.9% in GLORY-2, against none on placebo. In the highest American dose group the figure was 20% [9], [7].
  • A faster pulse. In a Chinese mid-stage trial the pulse rose by 5.82, 5.38 and 8.75 beats per minute across three dose levels, against 4.81 on placebo. In an early high-dose study the rise reached 17.4 beats per minute [25], [3].
  • No quotable warnings list. The only approved product information is Chinese and was not publicly retrievable on 10 September 2026. No list of contraindications can therefore be given here.
  • Products outside China. The American regulator names mazdutide among substances sold illegally under research labelling [26].

Tirzepatide. The pooled weight-loss trials covered 3,477 people on the drug [27].

  • Stomach and bowel. Nausea affected 25–29% against 8% on placebo, diarrhoea 19–23% against 8%, vomiting 8–13% against 2% and constipation 11–17% against 5% [27].
  • Stopping treatment. Side effects led 4.8–6.7% of participants to stop, against 3.4% on placebo [27].
  • Boxed warning. In rats, tirzepatide causes tumours in the C-cells of the thyroid gland, more often at higher doses and longer exposure. Whether this applies to people is unknown [2], [27].
  • Who must not take it. People with medullary thyroid cancer, personally or in the family, or with the inherited condition multiple endocrine neoplasia type 2 [2], [27].
  • Further label warnings. Pancreas inflammation, kidney damage from fluid loss, gallbladder trouble, low blood sugar alongside insulin and worsening diabetic eye disease [2], [27].

Why this page lists no doses. Tirzepatide is prescription-only wherever it is approved. Mazdutide is a prescription medicine in China and an unapproved experimental drug everywhere else. Choosing an amount belongs to the product information and the prescribing doctor, or to a supervised trial. This page therefore names doses only by their rank among those tested, never as an amount.

Mazdutide is licensed only in China, for long-term weight management since June 2025 and for type 2 diabetes since September 2025 [28]. The American, European, British and Canadian registers held no entry for it [29], [30], [31], [32]. Tirzepatide is an approved, prescription-only medicine in eight markets. The United States cleared it on 13 May 2022 and the European Union on 15 September 2022 [33], [34]. Neither drug is on the 2026 prohibited list in sport. Tirzepatide has been on the penalty-free monitoring programme since 1 January 2026 [35], [36]. For mazdutide, a full-text search of the list found no mention [37]. The monographs reflect the position on 10 and 6 September 2026 respectively.

Mazdutide

Status at a glance

MarketStatusDate
United StatesInvestigational—
European UnionInvestigational—
GermanyInvestigational—
United KingdomInvestigational—
AustraliaNot approved—
CanadaNot approved—
SwitzerlandNot approved—
Development stage
Approved
Strongest evidence
Phase 3 randomised trial
WADA status
Not listed
Last verified
2026-09-10
Version
1.0

This page lists no doses.

Tirzepatide

Status at a glance

MarketStatusDate
United StatesApproved, prescription only2022-05-13
European UnionApproved, prescription only2022-09-15
GermanyApproved, prescription only2022-09-15
United KingdomApproved, prescription only2023-11-08
AustraliaApproved, prescription only2023-07-10
CanadaApproved, prescription only2022-11-24
SwitzerlandApproved, prescription only2022-11-02
Development stage
Approved
Strongest evidence
Phase 3 randomised trial
WADA status
Not listed
Last verified
2026-09-06
Version
1.0

This page lists no doses.

Used together?

The myPeptides blend directory lists no product that combines mazdutide and tirzepatide. No study of the two drugs given together could be found in the sources reviewed for this page.

Both already act on the same GLP-1 receptor [1], [2]. More detail on each drug is in the monographs on mazdutide and tirzepatide.

Frequently asked questions

Which is better, mazdutide or tirzepatide?

The evidence does not say, because no trial comparing the two could be found. In GLORY-2, 461 Chinese adults with obesity lost 16.65% of body weight on mazdutide over 60 weeks. Tirzepatide was not part of that trial; in SURMOUNT-1, 2,539 adults with obesity and without diabetes lost up to 20.9% over 72 weeks. Different people, doses and trial lengths mean the figures cannot be ranked.

Is mazdutide or tirzepatide safer?

No trial comparing their safety could be found. Tirzepatide's record comes from approved US product information and a heart trial of 13,299 people. It carries a boxed warning about thyroid tumours in rats. Mazdutide's record comes from trials run almost entirely in China, with no published follow-up beyond 60 weeks, and includes a faster pulse. With both drugs, stomach and bowel complaints are the most common.

What is the difference between mazdutide and tirzepatide?

Both switch on the GLP-1 receptor. Mazdutide adds the receptor for glucagon and copies the gut hormone oxyntomodulin; tirzepatide adds the receptor for GIP and is built on that hormone. Mazdutide is licensed only in China, while tirzepatide is an approved prescription medicine in eight markets.

Can mazdutide and tirzepatide be taken together?

No study of the two drugs given together could be found, and the myPeptides blend directory lists no combination of them. Both act on the GLP-1 receptor. Mazdutide is licensed only in China, and tirzepatide is available only on prescription.

Has mazdutide been tested against tirzepatide?

No such trial could be found in the sources reviewed. Mazdutide's head-to-head trial DREAMS-3 compares it with semaglutide in 349 Chinese adults with type 2 diabetes and obesity; by 10 September 2026 only its design paper could be found. Both drugs have been tested against dulaglutide, but in separate trials that measured different things.

Is mazdutide approved in the United States or Europe?

No. China licensed it in June 2025 for long-term weight management and in September 2025 for type 2 diabetes. The American, European, British and Canadian registers held no entry for it on 10 September 2026. Tirzepatide, by contrast, has been approved in the United States since 13 May 2022 and in the European Union since 15 September 2022.

Are mazdutide and tirzepatide made by the same company?

Both molecules come from Eli Lilly. Tirzepatide carries the Lilly code LY3298176. Mazdutide was designed by Lilly under the code LY3305677 and licensed to Innovent Biologics for China, where it is called IBI362.

Are mazdutide and tirzepatide banned in sport?

Neither is on the 2026 prohibited list. A full-text search of the list found no mention of mazdutide. Tirzepatide has been on the monitoring programme since 1 January 2026, which carries no penalty.

How long do mazdutide and tirzepatide stay in the body?

The body takes about five days to clear half a dose of tirzepatide. For mazdutide the figure varies widely between people: in an early study of 24 participants it ranged from 7.3 to 44.8 days. In both, a fatty acid chain makes the peptide cling to albumin in the blood.

Sources

  1. FDA Global Substance Registration System. Substance record "Mazdutide", UNII MB76Z4IBZ5, UUID f7c54d54-5dd2-4052-90a6-61e7c9842bab. Retrieved 10 September 2026. https://gsrs.ncats.nih.gov/api/v1/substances(f7c54d54-5dd2-4052-90a6-61e7c9842bab)?view=full
  2. Tirzepatide injection (type 2 diabetes and cardiovascular product) — US Prescribing Information. Eli Lilly and Company, revision 8/2026. DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  3. Ji L et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 54:101691. PMID 36247927. PMCID PMC9561728. DOI 10.1016/j.eclinm.2022.101691
  4. Jiang H et al. (2022). A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature Communications 13:3613. PMID 35750681. PMCID PMC9232612. DOI 10.1038/s41467-022-31328-x
  5. Ji L et al. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine 39:101088. PMID 34430840. PMCID PMC8374649. DOI 10.1016/j.eclinm.2021.101088
  6. Luo Y et al. (2026). Mazdutide versus semaglutide for the treatment of type 2 diabetes and obesity: rationale, design and baseline data of the DREAMS-3 phase 3 trial. Contemporary Clinical Trials 160:108150. PMID 41260459. DOI 10.1016/j.cct.2025.108150
  7. Hsia SH et al. (2026). Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet Diabetes & Endocrinology, online 21 August 2026. PMID 42628555. DOI 10.1016/S2213-8587(26)00160-9
  8. Ji L et al.; GLORY-1 Investigators (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine 392(22):2215-2225. PMID 40421736. DOI 10.1056/NEJMoa2411528
  9. Gao L et al.; GLORY-2 Trial Investigators (2026). Treatment with mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial. JAMA 336(5):377-388. PMID 42251595. DOI 10.1001/jama.2026.8142
  10. Jastreboff AM, Aronne LJ, Ahmad NN et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine 387(3):205-216. PMID 35658024. DOI 10.1056/NEJMoa2206038
  11. Kamrul-Hasan ABM et al. (2026). Efficacy and safety of the dual glucagon-like peptide-1 and glucagon receptor agonist mazdutide in predominantly Chinese adults with obesity and/or type 2 diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism 28(10):8777-8794. PMID 42410325. PMCID PMC13538747. DOI 10.1111/dom.71058
  12. Zhu D et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature 652(8108):174-180. PMID 41407859. DOI 10.1038/s41586-025-10026-w
  13. Rosenstock J, Wysham C, Frías JP et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet 398(10295):143-155. PMID 34186022. DOI 10.1016/S0140-6736(21)01324-6
  14. Garvey WT, Frías JP, Jastreboff AM et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet 402(10402):613-626. PMID 37385275. DOI 10.1016/S0140-6736(23)01200-X
  15. Guo L et al.; DREAMS-2 investigators (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature 652(8108):181-188. PMID 41407860. DOI 10.1038/s41586-025-10031-z
  16. Nicholls SJ, Pavo I, Bhatt DL et al. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). New England Journal of Medicine 393(24):2409-2420. PMID 41406444. DOI 10.1056/NEJMoa2505928
  17. Frías JP, Davies MJ, Rosenstock J et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine 385(6):503-515. PMID 34170647. DOI 10.1056/NEJMoa2107519
  18. Aronne LJ, Horn DB, le Roux CW et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine 393(1):26-36. PMID 40353578. DOI 10.1056/NEJMoa2416394
  19. Packer M, Zile MR, Kramer CM et al. (2025). Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). New England Journal of Medicine 392(5):427-437. PMID 39555826. DOI 10.1056/NEJMoa2410027
  20. ClinicalTrials.gov API v2. Queries for "mazdutide", "IBI362" and "LY3305677" returned 43 study records; individual entries retrieved for NCT02972645, NCT03325387, NCT03928379, NCT04440345, NCT04466904, NCT04904913, NCT04965506, NCT05606913, NCT05607680, NCT05623839, NCT05628311, NCT05793450, NCT05815680, NCT06124807, NCT06143956, NCT06164873, NCT06184568, NCT06817356, NCT06884293, NCT06931028, NCT06937749, NCT07083154 and NCT07255209. Retrieved 10 September 2026. https://clinicaltrials.gov/api/v2/studies?query.intr=mazdutide
  21. Loomba R, Hartman ML, Lawitz EJ et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). New England Journal of Medicine 391(4):299-310. PMID 38856224. DOI 10.1056/NEJMoa2401943
  22. Xia H et al. (2025). Multiparametric MRI evaluation of liver fat and iron after glucagon-like peptide-1 receptor and glucagon receptor dual-agonist treatment in a high-fat diet-induced mouse model. Radiology 316(2):e243780. PMID 40828048. DOI 10.1148/radiol.243780
  23. Aronne LJ, Sattar N, Horn DB et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 331(1):38-48. PMID 38078870. DOI 10.1001/jama.2023.24945
  24. Malhotra A, Grunstein RR, Fietze I et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). New England Journal of Medicine 391(13):1193-1205. PMID 38912654. DOI 10.1056/NEJMoa2404881
  25. Ji L et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications 14:8289. PMID 38092790. PMCID PMC10719339. DOI 10.1038/s41467-023-44067-4
  26. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Page current as of 1 September 2026, retrieved 10 September 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  27. Tirzepatide injection (weight-management product) — US Prescribing Information. Eli Lilly and Company, revision 8/2026. DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  28. Shirley M (2025). Mazdutide: first approval. Drugs 85(12):1621-1627. PMID 41028652. DOI 10.1007/s40265-025-02249-y
  29. openFDA. Drugs@FDA, drug label and enforcement queries for "mazdutide"; each returned no match. Control query for semaglutide in the same run returned results. Retrieved 10 September 2026. https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:mazdutide
  30. European Commission. Community Register of medicinal products for human use; no entry for "mazdutide", against five for semaglutide in the same document. Retrieved 10 September 2026. https://ec.europa.eu/health/documents/community-register/html/reg_hum_act.htm
  31. electronic medicines compendium. Search "mazdutide" returned "No search results"; control search for semaglutide returned 20 results. Retrieved 10 September 2026. https://www.medicines.org.uk/emc/search?q=mazdutide
  32. Health Canada. Drug Product Database API, active ingredient query "mazdutide"; empty result. Control query for semaglutide returned entries. Retrieved 10 September 2026. https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=mazdutide
  33. Drugs@FDA / openFDA, NDA 215866, approval and supplement history. Retrieved 6 September 2026. https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22
  34. European Medicines Agency, European public assessment report for tirzepatide, authorised 15 September 2022, revision 21 of 28 August 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
  35. World Anti-Doping Agency, Prohibited List. Retrieved 6 September 2026; tirzepatide is not listed for 2026. https://www.wada-ama.org/en/prohibited-list
  36. Nationale Anti Doping Agentur Deutschland (NADA). WADA publishes Prohibited List 2026. https://www.nada.de/en/service/news/news-detail/wada-publishes-prohibited-list-2026
  37. World Anti-Doping Agency. The 2026 Prohibited List, in force from 1 January 2026; official text published as annex to BGBl. III No. 219 of 30 December 2025. Sections S2 and S4.4 reviewed in full; full-text search for "mazdutide", "glucagon", "GLP-1" and "incretin" returned no hits. Retrieved 10 September 2026.

Further reading

Last reviewed: September 2026

Take myPeptides with you

Track doses, plans and progress on your phone — end-to-end encrypted.

Open in app App Store Join the beta

This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.